Avantyx is structured around prevention and cure of Peripheral Neuropathy (CIPN) - a nerve-damaging side effect of antineoplastic agents used in cancer treatment. Recent data suggest that some 70% of patients undergoing chemotherapy will develop the condition. The condition is defined as causing pain, tingling, temperature sensitivity, and numbness in the hands and feet. With Avantyx founders having studied the root cause of peripheral neuropathy for many years, what may be a breakthrough discovery - identification of a unique mechanism that causes peripheral - may have been made. Based on those finding, the team is working on a compound (potentially) not only could cure - but will also prevent the condition from occurring in the first place .. improving patient survival rates and quality of life for all those involved.
